Patient Engagement Synapse
  • Join now
  • Login
COVID-19 hub
  • Home
  • People
  • Organizations
  • Initiatives
  • Events
  • Resources
  • Conditions
  • Trainings
  • Patient Pledge
    • Take the Pledge
    • The Pledge Record
  • Reports
  • Join now
  • Login

Parkinson's Disease

Neurology
  • Overview
  • Organizations 21
  • People 10
  • Initiatives 8
  • Resources 3
  • Events 0

A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.


Synonyms

Parkinson's disease , paralysis agitans

Related diseases

CHCHD2 Parkinson disease , CLN12 disease , DNAJC13 hereditary late onset Parkinson disease , DNAJC6 Parkinson disease , EIF4G1 hereditary late onset Parkinson disease , GIGYF2 hereditary late onset Parkinson disease , Kufor-Rakeb syndrome , LOPD , LRRK2 Parkinson disease , PARK10 , PARK12 , PARK14 , PARK16 , PARK22 , PARK23 , PARK3 , PARK7 Parkinson disease , PARK9 , PINK1 Parkinson disease , PLA2G6 hereditary late onset Parkinson disease , PLA2G6-related dystonia-parkinsonism , PRKN young-onset Parkinson disease , Pallidopyramidal syndrome , Parkinson disease 11, autosomal dominant, susceptibility to , Parkinson disease 17 , Parkinson disease 18, autosomal dominant, susc Display more information eptibility to , Parkinson disease 21 , Parkinson disease 22, autosomal dominant , Parkinson disease 22, autosomal dominant; PARK22 , Parkinson disease 23, autosomal recessive early-onset , Parkinson disease 5, autosomal dominant, susceptibility to , Parkinson disease caused by mutation in CHCHD2 , Parkinson disease caused by mutation in DNAJC6 , Parkinson disease caused by mutation in LRRK2 , Parkinson disease caused by mutation in PARK7 , Parkinson disease caused by mutation in PINK1 , Parkinson disease caused by mutation in SYNJ1 , Parkinson disease caused by mutation in VPS35 , Parkinson disease type 17 , Parkinson disease type 21 , Parkinson disease, mitochondrial , SYNJ1 Parkinson disease , UCHL1 young-onset Parkinson disease , VPS13C young-onset Parkinson disease , VPS35 Parkinson disease , YOPD , autosomal dominant Lewy body Parkinson disease 4 , autosomal dominant Parkinson disease 1 , autosomal dominant Parkinson disease 17 , autosomal dominant Parkinson disease 4 , autosomal dominant Parkinson disease 8 , autosomal dominant Parkinson disease type 1 , autosomal dominant Parkinson disease type 4 , autosomal dominant Parkinson disease type 8 , autosomal dominant late-onset Parkinson disease , autosomal recessive Parkinson disease 14 , autosomal recessive Parkinson disease 9 , autosomal recessive Parkinson disease type 14 , autosomal recessive early-onset Parkinson disease 15 , autosomal recessive early-onset Parkinson disease 23 , autosomal recessive early-onset Parkinson disease 6 , autosomal recessive early-onset Parkinson disease 7 , autosomal recessive early-onset Parkinson disease type 15 , autosomal recessive early-onset Parkinson disease type 6 , autosomal recessive early-onset Parkinson disease type 7 , autosomal recessive early-onset Parksinson disease 23 , autosomal recessive early-onset Parksinson disease type 23 , autosomal recessive juvenile Parkinson disease 2 , autosomal recessive juvenile Parkinson disease type 2 , autosomal recessive juvenile onset Parkinson disease 9 , dystonia-Parkinsonism Adult-onset , dystonia-parkinsonism, Paisan-Ruiz type , early-onset Parkinson disease , early-onset Parkinson disease 20 , early-onset Parkinson disease 6 , early-onset Parkinson disease type 20 , hereditary late onset Parkinson disease , hereditary late onset Parkinson disease caused by mutation in DNAJC13 , hereditary late onset Parkinson disease caused by mutation in EIF4G1 , hereditary late onset Parkinson disease caused by mutation in GIGYF2 , hereditary late onset Parkinson disease caused by mutation in PLA2G6 , juvenile onset Parkinson disease 19A , juvenile onset Parkinson disease type 19A , juvenile-onset Parkinson disease , late-onset Parkinson disease , pallidopyramidal syndrome , paralysis agitans, juvenile, of Hunt , parkinsonian-pyramidal syndrome , parkinsonism due to ATP13A2 deficiency , young-onset Parkinson disease , young-onset Parkinson disease caused by mutation in PRKN , young-onset Parkinson disease caused by mutation in UCHL1 , young-onset Parkinson disease caused by mutation in VPS13C Display less info
see all

Organizations

AbbVie

Pharmaceutical Company

Global
2 Users
4 Initiatives
2 Resources

Association of Patients with Neurodegenerative Conditions

Patient Advocacy Organization

Romania
1 User
0 Initiatives
0 Resources

AstraZeneca

Pharmaceutical Company

Global
92 Users
13 Initiatives
3 Resources

Cure PSP - Patient Engagement Program

Patient Advocacy Organization

North America
1 User
1 Initiative
0 Resources

F. Hoffmann La Roche

Pharmaceutical Company

Global
24 Users
26 Initiatives
12 Resources

George Clinical

Academic Medical Center/Hospital/Practice

Global
1 User
0 Initiatives
0 Resources

Ipsen pharma

Pharmaceutical Company

Global
2 Users
4 Initiatives
0 Resources

Janssen - Johnson & Johnson

Pharmaceutical Company

Global
21 Users
32 Initiatives
14 Resources

Leapcure

Patient Advocacy Organization

Global
1 User
0 Initiatives
0 Resources

Lundbeck

Pharmaceutical Company

Global
1 User
2 Initiatives
0 Resources

Michael J Fox Foundation

Patient Advocacy Organization

Europe, North America
1 User
1 Initiative
0 Resources

Neurology Patient Initiative

Start Up

Global
1 User
0 Initiatives
0 Resources

Novartis

Pharmaceutical Company

Global
135 Users
83 Initiatives
28 Resources

Parkinson's Disease Foundation

Patient Advocacy Organization

North America
2 Users
9 Initiatives
2 Resources

Parkinsons UK

Patient Advocacy Organization

United Kingdom
4 Users
14 Initiatives
4 Resources
see all

People

Andrew Cassy

Patient research advocate for Parkinsons UK

Woodbridge, United Kingdom

Parkinsons UK

Pledge icon

Helen Matthews

The Cure Parkinson's Trust

London, United Kingdom

The Cure Parkinson's Trust

Irma Chighladze

Tbilisi, Georgia

Jennie Maris

PPIE and Comms Co-lead at the NIHR Sheffield BRC

Sheffield, United Kingdom

NIHR Sheffield Biomedical Research Centre (BRC)

Karlin Schroeder

Associate Vice President, Community Engagement

Parkinson's Disease Foundation

Pledge icon

Laura Evans

Sheffield, United Kingdom

NIHR Sheffield Biomedical Research Centre (BRC)

Matt Eagles

Positivity Activist & Head of Patient Engagement at HAVAS LYNX

Manchester, United Kingdom

Matthew May

Patient Partnership Director

Switzerland

F. Hoffmann La Roche

Natasha Ratcliffe

Research Involvement Manager

London, United Kingdom

Parkinsons UK

Pledge icon

Sonia Sgro

Global Head of Patient Advocacy presso Zambon

see all

Initiatives

AIDA Project

UCB

Europe

Conducting rigorous qualitative research with and for patients to provide novel patient-centered perspectives and insights on diseases and treatments

Pharmerit International

Global

Consulting a patient and carer group on the delivery of Exoskeleton assisted walking to aid cardiovascular fitness in patients with gait problems due to Multiple Sclerosis

NIHR Sheffield Biomedical Research Centre (BRC)

United Kingdom

Currently underway

Consulting a patient and carer group on the design and delivery of a proof of concept drug repurposing trial in Parkinson’s Disease

NIHR Sheffield Biomedical Research Centre (BRC)

United Kingdom

Currently underway

Fox Trial Finder

Michael J Fox Foundation

Europe, North America

HeadUp Collar: Co-creation of a new cervical orthosis for patients with Motor Neuron Disease/ neck weakness

NIHR Sheffield Biomedical Research Centre (BRC)

United Kingdom

Completed over one year ago

Parkinson's Advocates in Research

Parkinson's Disease Foundation

North America

Unmet needs in Parkinson's research

Parkinsons UK

United Kingdom

Resources

TF
MV

Alleati per la Salute_presentation

19 May 2020 Other

Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life

22 Dec 2020 Research report

The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities

22 Dec 2020 Publication

Do you need help?

  • Contact us
  • Help Center
  • Latest updates
  • Cookie privacy options

Useful links

  • About us
  • Features
  • Search tool
  • Terms and Conditions
  • Privacy Policy
  • Geographical
  • Medical scope
  • Timeline
  • Patient matrix
  • Medicine lifecycle

Join our newsletter

Get the latest information on Patient Focused Medicines Development and stay connected with our activities.

5.3.0@prod
© Copyright SYNAPSE 2021. All Rights Reserved Powered by The Synergist.